[Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial].
A A
AA
Liakishev
D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D014943:Global Health; D006801:Humans; D015994:Incidence; D008297:Male; D016491:Peripheral Vascular Diseases / Q000188:drug therapy* / Q000453:epidemiology; D017257:Ramipril / Q000627:therapeutic use*; D012307:Risk Factors; D000077333:Telmisartan; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D017257:Ramipril; D000077333:Telmisartan